Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates

被引:9
作者
Drago, L [1 ]
De Vecchi, E [1 ]
Lombardi, A [1 ]
Nicola, L [1 ]
Valli, M [1 ]
Gismondo, MR [1 ]
机构
[1] Univ Milan, L Sacco Teaching Hosp, Lab Clin Microbiol, I-20157 Milan, Italy
关键词
Bacillus anthracis; anthrax; fluoroquinolones; penicillin; meropenem; rokitamycin; macrolides; in vitro susceptibility testing;
D O I
10.1093/jac/dkg006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study aimed to evaluate the bactericidal rates of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against seven isolates of Bacillus anthracis clinically isolated between 1960 and 1970. After determination of MIC and MBC, time-kill experiments were carried out. Antimicrobial activity was evaluated at concentrations equal to 1 x, 2 x, 4 x and 8 x MIC after 0, 3, 6, 12 and 24 h of incubation with the drugs. Bactericidal activity was defined as a decrease in bacterial count of at least 3 log(10). All the isolates were susceptible to all the antibiotics, by considering the antistaphylococcal breakpoints. Levofloxacin was bactericidal at 1 x MIC after 24 h and at 4 x MIC after 12 h, and gatifloxacin was bactericidal at 2 x MIC after 24 h and at 8 x MIC after 12 h. Meropenem, rokitamycin and penicillin also showed bactericidal activity at concentrations of 4 x and 8 x MIC, respectively, but only after 24 h incubation; after the same time, meropenem and rokitamycin showed a more marked killing than penicillin at 2 x MIC.
引用
收藏
页码:1059 / 1063
页数:5
相关论文
共 13 条
[1]  
[Anonymous], MANUAL CLIN MICROBIO
[2]   In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones [J].
Brook, I ;
Elliott, TB ;
Pryor, HI ;
Sautter, TE ;
Gnade, BT ;
Thakar, JH ;
Knudson, GB .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (06) :559-562
[3]   Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000 [J].
Cavallo, JD ;
Ramisse, F ;
Girardet, M ;
Vaissaire, J ;
Mock, M ;
Hernandez, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) :2307-2309
[4]  
Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1014
[5]   Anthrax [J].
Dixon, TC ;
Meselson, M ;
Guillemin, J ;
Hanna, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :815-826
[6]   ANTIMICROBIAL SUSCEPTIBILITY OF BACILLUS-ANTHRACIS [J].
DOGANAY, M ;
AYDIN, N .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (03) :333-335
[7]   Anthrax as a biological weapon - Medical and public health management [J].
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Friedlander, AM ;
Hauer, J ;
McDade, J ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1735-1745
[8]   THE SVERDLOVSK ANTHRAX OUTBREAK OF 1979 [J].
MESELSON, M ;
GUILLEMIN, J ;
HUGHJONES, M ;
LANGMUIR, A ;
POPOVA, I ;
SHELOKOV, A ;
YAMPOLSKAYA, O .
SCIENCE, 1994, 266 (5188) :1202-1208
[9]   Antimicrobial susceptibility testing of Bacillus anthracis:: Comparison of results obtained by using National Committee for Clinical Laboratory Standards broth microdilution reference and etest agar gradient diffusion methods [J].
Mohammed, MJ ;
Marston, CK ;
Popovic, T ;
Weyant, RS ;
Tenover, FC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) :1902-1907
[10]  
National Committee for Clinical Laboratory Standards, 2001, PERF STAND ANT SUS S